BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26585822)

  • 1. Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.
    Guo L; Wu H; Zhu J; Zhang C; Ma J; Lan J; Xie X
    Life Sci; 2015 Dec; 143():217-24. PubMed ID: 26585822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning-based models for genomic predicting neoadjuvant chemotherapeutic sensitivity in cervical cancer.
    Guo L; Wang W; Xie X; Wang S; Zhang Y
    Biomed Pharmacother; 2023 Mar; 159():114256. PubMed ID: 36652730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
    Chung HH; Kim MK; Kim JW; Park NH; Song YS; Kang SB; Lee HP
    Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
    Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
    Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population.
    Wang Y; Lin L; Xu H; Li T; Zhou Y; Dan H; Jiang L; Liao G; Zhou M; Li L; Zeng X; Li J; Chen Q
    J Oral Pathol Med; 2015 Jan; 44(1):45-50. PubMed ID: 25060489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer.
    Guo L; Wang W; Xie X; Wang S; Zhang Y
    Biomed Pharmacother; 2023 May; 161():114518. PubMed ID: 36906972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
    Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
    Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Guo Q; Lu T; Chen Y; Su Y; Zheng Y; Chen Z; Chen C; Lin S; Pan J; Yuan X
    Sci Rep; 2016 Nov; 6():37576. PubMed ID: 27876891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
    Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.
    Faried LS; Faried A; Kanuma T; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Oncol Rep; 2006 Jul; 16(1):57-63. PubMed ID: 16786123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
    Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
    Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
    Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
    Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience.
    Huang X; Lan C; Huang H; Zhang Y; Huang H; Cao X; Huang Y; Guo Y; Wan T; Liu J
    Expert Opin Pharmacother; 2011 Feb; 12(2):165-73. PubMed ID: 21226631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.